Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sierra Oncology Inc 2150 -885 WEST GEORGIA STREET VANCOUVER A1 V6C 3E8 CAN

P: 604-558-6536

Description:

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada.

Key Statistics

Overview:

Market Capitalization, $K 143,476
Shares Outstanding, K 74,340
Annual Sales, $ 0 K
Annual Net Income, $ -42,020 K
36-Month Beta 2.18
% of Insider Shareholders 5.61%
% of Institutional Shareholders 64.23%

Growth:

1-Year Total Return 10.62%
3-Year Total Return -88.67%
5-Year Total Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 02/27/18
Next Earnings Date 11/14/18
Earnings Per Share ttm -0.55
EPS Growth vs. Prev Qtr 15.79%
EPS Growth vs. Prev Year 20.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

SRRA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -2.46
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -39.19
Return-on-Assets (Before Tax) -36.95
Net Margin % N/A
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.19
Book Value/Share 1.62
Interest Coverage N/A
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar